Drug shows promise for new uses, firm says

April 18, 2007 04:02 PM E-mail| |Comments ()| Text size +

EPIX Pharmaceuticals Inc., of Lexington, today said there were positive results in cognitive development recorded from early-stage clinical trials of PRX-07034, its anti-obesity drug, which is being tested for possible use against Alzheimer’s disease and schizophrenia.

The early tests were for ascending doses and included 33 subjects in an in-patient setting. Subjects tolerated the doses and ‘‘no serious adverse events were reported,’’ according to a news release.

The results were announced at a presentation by Kimberley S. Gannon, senior director of biology for EPIX, at a conference on Alzheimer’s in the Dominican Republic.
(By Thomas C. Palmer Jr., Globe staff)

Email this article

Invalid email address
Invalid email address

Sending your article

Your article has been sent.

Col3